No Data
Express News | Adocia SA - Phase 3 Topline Results Expected in H1 2025
ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone Lispro, Milestone Associated With a $10 Million Payment
Tonghua Dongbao Pharmaceutical Co., Ltd.'s (SHSE:600867) Has Been On A Rise But Financial Prospects Look Weak: Is The Stock Overpriced?
Tonghua Dongbao Pharmaceutical Completes Phase 1a Trial for Diabetes Injection
Tonghua Dongbao Pharmaceutical (600867.SH): The THDBH120 has received the summary report of phase I clinical trial, and the research results have reached the main endpoint objectives.
Tonghua Dongbao Pharmaceutical (600867.SH) issued a statement that its wholly-owned subsidiary Dongbao Zixing (Hangzhou) Biomedical Co., Ltd...
Tonghua Dongbao Pharmaceutical (600867.SH) has repurchased 0.98% of its shares at a cost of 0.149 billion yuan.
tonghua dongbao pharmaceutical (600867.SH) announced that as of the end of November 2024, the company had completed the centralized bidding transaction...
Insufficient Growth At Tonghua Dongbao Pharmaceutical Co., Ltd. (SHSE:600867) Hampers Share Price
